Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
UroGen Pharma Ltd.
URGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.8B
$37.39
▼ -1.45%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$12.89 - $39.59
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 192.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary RTGel reverse thermal gelation hydrogel technology enabling superior drug delivery and tissue retention
- Strategic partnerships with Allergan and Agenus providing development and commercialization resources
- Collaboration with MD Anderson Cancer Center enhancing clinical credibility and research capabilities
- First-mover advantage in intravesical delivery for non-muscle invasive urothelial cancers
Bear Case
2 risks
- Above-average volatility (beta 1.6).
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Strong growth ahead
UGN-102 Phase III clinical trial progression toward FDA approval for bladder and upper tract cancers
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Hot
+101.6% over 3m
Quality
Excellent
High-growth business (53% revenue growth, 90% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying URGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 6, 2026
Reported EPS of -$0.47 vs -$0.48 consensus (+2.6% surprise). Revenue of $51.0M vs $44.8M expected (+13.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+2.6%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
+4%
+8%
+11%
+9%
+54%
+152%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$21.8M
$25.2M
$24.6M
$20.3M
$24.2M
$27.5M
$37.8M
$51.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
-46.3%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$42.50
▲ +13.7% vs $37.39
Latest: HC Wainwright · Jun 3, 2026
2 analysts covering